United Therapeutics Corporation (FRA:UTH)
Germany · Delayed Price · Currency is EUR 412.00
+0.20 (0.05%)
Last updated: Nov 24, 2025, 11:02 AM CET
United Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 3,128 | 2,877 | 2,328 | 1,936 | 1,686 | 1,483 | Upgrade |
| 3,128 | 2,877 | 2,328 | 1,936 | 1,686 | 1,483 | Upgrade | |
Revenue Growth (YoY) | 13.50% | 23.63% | 20.20% | 14.88% | 13.63% | 2.38% | Upgrade |
Cost of Revenue | 356.9 | 309.7 | 257.5 | 151.6 | 122.5 | 108.1 | Upgrade |
Gross Profit | 2,772 | 2,568 | 2,070 | 1,785 | 1,563 | 1,375 | Upgrade |
Selling, General & Admin | 705.6 | 640.4 | 476 | 472.8 | 466.1 | 421.1 | Upgrade |
Research & Development | 544.3 | 481 | 408 | 322.9 | 410 | 357.7 | Upgrade |
Operating Expenses | 1,250 | 1,121 | 884 | 795.7 | 876.1 | 778.8 | Upgrade |
Operating Income | 1,522 | 1,446 | 1,186 | 989 | 686.9 | 596.4 | Upgrade |
Interest Expense | -24.3 | -42.9 | -59.3 | -32.4 | -18.6 | -23.5 | Upgrade |
Interest & Investment Income | 198.1 | 199.1 | 162.7 | 45.2 | 16.7 | 28.6 | Upgrade |
Other Non Operating Income (Expenses) | 4.5 | -1.4 | -27.3 | -38.3 | 43.8 | 26.4 | Upgrade |
EBT Excluding Unusual Items | 1,700 | 1,601 | 1,262 | 963.5 | 728.8 | 627.9 | Upgrade |
Gain (Loss) on Sale of Investments | -3.6 | 9 | 15.8 | -1.7 | -2.3 | 16.4 | Upgrade |
Asset Writedown | -21.7 | - | -3.6 | -11.2 | -132.6 | -5.4 | Upgrade |
Legal Settlements | -8.2 | -71.1 | - | - | - | - | Upgrade |
Pretax Income | 1,666 | 1,539 | 1,274 | 950.6 | 593.9 | 638.9 | Upgrade |
Income Tax Expense | 394.7 | 343.9 | 289.5 | 223.3 | 118.1 | 124.1 | Upgrade |
Net Income | 1,272 | 1,195 | 984.8 | 727.3 | 475.8 | 514.8 | Upgrade |
Net Income to Common | 1,272 | 1,195 | 984.8 | 727.3 | 475.8 | 514.8 | Upgrade |
Net Income Growth | 14.47% | 21.36% | 35.41% | 52.86% | -7.58% | - | Upgrade |
Shares Outstanding (Basic) | 45 | 45 | 47 | 46 | 45 | 44 | Upgrade |
Shares Outstanding (Diluted) | 48 | 49 | 50 | 49 | 47 | 45 | Upgrade |
Shares Change (YoY) | -1.38% | -2.41% | 2.47% | 2.54% | 6.05% | 1.83% | Upgrade |
EPS (Basic) | 28.47 | 26.44 | 21.04 | 15.98 | 10.60 | 11.65 | Upgrade |
EPS (Diluted) | 26.38 | 24.64 | 19.81 | 15.00 | 10.06 | 11.54 | Upgrade |
EPS Growth | 16.08% | 24.38% | 32.07% | 49.10% | -12.83% | - | Upgrade |
Free Cash Flow | 1,122 | 1,081 | 747.6 | 663.7 | 477.4 | 696.4 | Upgrade |
Free Cash Flow Per Share | 23.28 | 22.28 | 15.04 | 13.69 | 10.09 | 15.61 | Upgrade |
Gross Margin | 88.59% | 89.24% | 88.94% | 92.17% | 92.73% | 92.71% | Upgrade |
Operating Margin | 48.64% | 50.26% | 50.96% | 51.08% | 40.75% | 40.21% | Upgrade |
Profit Margin | 40.65% | 41.53% | 42.31% | 37.56% | 28.23% | 34.71% | Upgrade |
Free Cash Flow Margin | 35.86% | 37.55% | 32.12% | 34.28% | 28.32% | 46.95% | Upgrade |
EBITDA | 1,604 | 1,519 | 1,239 | 1,040 | 736.8 | 646.3 | Upgrade |
EBITDA Margin | 51.28% | 52.78% | 53.24% | 53.73% | 43.71% | 43.57% | Upgrade |
D&A For EBITDA | 82.5 | 72.5 | 53.2 | 51.3 | 49.9 | 49.9 | Upgrade |
EBIT | 1,522 | 1,446 | 1,186 | 989 | 686.9 | 596.4 | Upgrade |
EBIT Margin | 48.64% | 50.26% | 50.96% | 51.08% | 40.75% | 40.21% | Upgrade |
Effective Tax Rate | 23.69% | 22.35% | 22.72% | 23.49% | 19.89% | 19.42% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.